Hematological Malignancy Treatment Market, Global Outlook and Forecast 2022-2028

July 2022 | 103 pages | ID: H6402AF35A4DEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Hematological Malignancy Treatment in Global, including the following market information:

Global Hematological Malignancy Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Hematological Malignancy Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Monoclonal Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hematological Malignancy Treatment include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hematological Malignancy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hematological Malignancy Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Hematological Malignancy Treatment Market Segment Percentages, by Type, 2021 (%)

• Monoclonal Antibody
• Immunomodulatory Drug
• Tyrosine Kinase Inhibitor
• Proteasome Inhibitors
• Others

Global Hematological Malignancy Treatment Market, by Indication, 2017-2022, 2023-2028 ($ millions)

Global Hematological Malignancy Treatment Market Segment Percentages, by Indication, 2021 (%)

• ALL
• CLL
• AML
• NHL
• DLBCL
• MM
• Others

Global Hematological Malignancy Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Hematological Malignancy Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hematological Malignancy Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Hematological Malignancy Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Roche
• Celgene
• Novartis
• Bristol-Myers Squibb
• Johnson & Johnson
• Merck & Co.
• AstraZeneca
• Pfizer
• Amgen
• Eli Lilly
• AbbVie
• Takeda
• Sanofi
• Bayer
• Biogen Idec

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Hematological Malignancy Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Indication
1.3 Global Hematological Malignancy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL HEMATOLOGICAL MALIGNANCY TREATMENT OVERALL MARKET SIZE

2.1 Global Hematological Malignancy Treatment Market Size: 2021 VS 2028
2.2 Global Hematological Malignancy Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Hematological Malignancy Treatment Players in Global Market
3.2 Top Global Hematological Malignancy Treatment Companies Ranked by Revenue
3.3 Global Hematological Malignancy Treatment Revenue by Companies
3.4 Top 3 and Top 5 Hematological Malignancy Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hematological Malignancy Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hematological Malignancy Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Hematological Malignancy Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Hematological Malignancy Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Hematological Malignancy Treatment Market Size Markets, 2021 & 2028
  4.1.2 Monoclonal Antibody
  4.1.3 Immunomodulatory Drug
  4.1.4 Tyrosine Kinase Inhibitor
  4.1.5 Proteasome Inhibitors
  4.1.6 Others
4.2 By Type - Global Hematological Malignancy Treatment Revenue & Forecasts
  4.2.1 By Type - Global Hematological Malignancy Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Hematological Malignancy Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Hematological Malignancy Treatment Market Size, 2021 & 2028
  5.1.2 ALL
  5.1.3 CLL
  5.1.4 AML
  5.1.5 NHL
  5.1.6 DLBCL
  5.1.7 MM
  5.1.8 Others
5.2 By Indication - Global Hematological Malignancy Treatment Revenue & Forecasts
  5.2.1 By Indication - Global Hematological Malignancy Treatment Revenue, 2017-2022
  5.2.2 By Indication - Global Hematological Malignancy Treatment Revenue, 2023-2028
  5.2.3 By Indication - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Hematological Malignancy Treatment Market Size, 2021 & 2028
6.2 By Region - Global Hematological Malignancy Treatment Revenue & Forecasts
  6.2.1 By Region - Global Hematological Malignancy Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Hematological Malignancy Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Hematological Malignancy Treatment Revenue, 2017-2028
  6.3.2 US Hematological Malignancy Treatment Market Size, 2017-2028
  6.3.3 Canada Hematological Malignancy Treatment Market Size, 2017-2028
  6.3.4 Mexico Hematological Malignancy Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Hematological Malignancy Treatment Revenue, 2017-2028
  6.4.2 Germany Hematological Malignancy Treatment Market Size, 2017-2028
  6.4.3 France Hematological Malignancy Treatment Market Size, 2017-2028
  6.4.4 U.K. Hematological Malignancy Treatment Market Size, 2017-2028
  6.4.5 Italy Hematological Malignancy Treatment Market Size, 2017-2028
  6.4.6 Russia Hematological Malignancy Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Hematological Malignancy Treatment Market Size, 2017-2028
  6.4.8 Benelux Hematological Malignancy Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Hematological Malignancy Treatment Revenue, 2017-2028
  6.5.2 China Hematological Malignancy Treatment Market Size, 2017-2028
  6.5.3 Japan Hematological Malignancy Treatment Market Size, 2017-2028
  6.5.4 South Korea Hematological Malignancy Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Hematological Malignancy Treatment Market Size, 2017-2028
  6.5.6 India Hematological Malignancy Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Hematological Malignancy Treatment Revenue, 2017-2028
  6.6.2 Brazil Hematological Malignancy Treatment Market Size, 2017-2028
  6.6.3 Argentina Hematological Malignancy Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Hematological Malignancy Treatment Revenue, 2017-2028
  6.7.2 Turkey Hematological Malignancy Treatment Market Size, 2017-2028
  6.7.3 Israel Hematological Malignancy Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Hematological Malignancy Treatment Market Size, 2017-2028
  6.7.5 UAE Hematological Malignancy Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Roche
  7.1.1 Roche Corporate Summary
  7.1.2 Roche Business Overview
  7.1.3 Roche Hematological Malignancy Treatment Major Product Offerings
  7.1.4 Roche Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.1.5 Roche Key News
7.2 Celgene
  7.2.1 Celgene Corporate Summary
  7.2.2 Celgene Business Overview
  7.2.3 Celgene Hematological Malignancy Treatment Major Product Offerings
  7.2.4 Celgene Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.2.5 Celgene Key News
7.3 Novartis
  7.3.1 Novartis Corporate Summary
  7.3.2 Novartis Business Overview
  7.3.3 Novartis Hematological Malignancy Treatment Major Product Offerings
  7.3.4 Novartis Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.3.5 Novartis Key News
7.4 Bristol-Myers Squibb
  7.4.1 Bristol-Myers Squibb Corporate Summary
  7.4.2 Bristol-Myers Squibb Business Overview
  7.4.3 Bristol-Myers Squibb Hematological Malignancy Treatment Major Product Offerings
  7.4.4 Bristol-Myers Squibb Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.4.5 Bristol-Myers Squibb Key News
7.5 Johnson & Johnson
  7.5.1 Johnson & Johnson Corporate Summary
  7.5.2 Johnson & Johnson Business Overview
  7.5.3 Johnson & Johnson Hematological Malignancy Treatment Major Product Offerings
  7.5.4 Johnson & Johnson Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.5.5 Johnson & Johnson Key News
7.6 Merck & Co.
  7.6.1 Merck & Co. Corporate Summary
  7.6.2 Merck & Co. Business Overview
  7.6.3 Merck & Co. Hematological Malignancy Treatment Major Product Offerings
  7.6.4 Merck & Co. Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.6.5 Merck & Co. Key News
7.7 AstraZeneca
  7.7.1 AstraZeneca Corporate Summary
  7.7.2 AstraZeneca Business Overview
  7.7.3 AstraZeneca Hematological Malignancy Treatment Major Product Offerings
  7.7.4 AstraZeneca Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.7.5 AstraZeneca Key News
7.8 Pfizer
  7.8.1 Pfizer Corporate Summary
  7.8.2 Pfizer Business Overview
  7.8.3 Pfizer Hematological Malignancy Treatment Major Product Offerings
  7.8.4 Pfizer Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.8.5 Pfizer Key News
7.9 Amgen
  7.9.1 Amgen Corporate Summary
  7.9.2 Amgen Business Overview
  7.9.3 Amgen Hematological Malignancy Treatment Major Product Offerings
  7.9.4 Amgen Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.9.5 Amgen Key News
7.10 Eli Lilly
  7.10.1 Eli Lilly Corporate Summary
  7.10.2 Eli Lilly Business Overview
  7.10.3 Eli Lilly Hematological Malignancy Treatment Major Product Offerings
  7.10.4 Eli Lilly Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.10.5 Eli Lilly Key News
7.11 AbbVie
  7.11.1 AbbVie Corporate Summary
  7.11.2 AbbVie Business Overview
  7.11.3 AbbVie Hematological Malignancy Treatment Major Product Offerings
  7.11.4 AbbVie Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.11.5 AbbVie Key News
7.12 Takeda
  7.12.1 Takeda Corporate Summary
  7.12.2 Takeda Business Overview
  7.12.3 Takeda Hematological Malignancy Treatment Major Product Offerings
  7.12.4 Takeda Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.12.5 Takeda Key News
7.13 Sanofi
  7.13.1 Sanofi Corporate Summary
  7.13.2 Sanofi Business Overview
  7.13.3 Sanofi Hematological Malignancy Treatment Major Product Offerings
  7.13.4 Sanofi Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.13.5 Sanofi Key News
7.14 Bayer
  7.14.1 Bayer Corporate Summary
  7.14.2 Bayer Business Overview
  7.14.3 Bayer Hematological Malignancy Treatment Major Product Offerings
  7.14.4 Bayer Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.14.5 Bayer Key News
7.15 Biogen Idec
  7.15.1 Biogen Idec Corporate Summary
  7.15.2 Biogen Idec Business Overview
  7.15.3 Biogen Idec Hematological Malignancy Treatment Major Product Offerings
  7.15.4 Biogen Idec Hematological Malignancy Treatment Revenue in Global Market (2017-2022)
  7.15.5 Biogen Idec Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Hematological Malignancy Treatment Market Opportunities & Trends in Global Market
Table 2. Hematological Malignancy Treatment Market Drivers in Global Market
Table 3. Hematological Malignancy Treatment Market Restraints in Global Market
Table 4. Key Players of Hematological Malignancy Treatment in Global Market
Table 5. Top Hematological Malignancy Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hematological Malignancy Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hematological Malignancy Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hematological Malignancy Treatment Product Type
Table 9. List of Global Tier 1 Hematological Malignancy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hematological Malignancy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Hematological Malignancy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hematological Malignancy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hematological Malignancy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Indication – Global Hematological Malignancy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Indication - Hematological Malignancy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Indication - Hematological Malignancy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Hematological Malignancy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hematological Malignancy Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hematological Malignancy Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hematological Malignancy Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hematological Malignancy Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hematological Malignancy Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hematological Malignancy Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hematological Malignancy Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Roche Corporate Summary
Table 31. Roche Hematological Malignancy Treatment Product Offerings
Table 32. Roche Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Celgene Corporate Summary
Table 34. Celgene Hematological Malignancy Treatment Product Offerings
Table 35. Celgene Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Hematological Malignancy Treatment Product Offerings
Table 38. Novartis Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Bristol-Myers Squibb Corporate Summary
Table 40. Bristol-Myers Squibb Hematological Malignancy Treatment Product Offerings
Table 41. Bristol-Myers Squibb Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Johnson & Johnson Corporate Summary
Table 43. Johnson & Johnson Hematological Malignancy Treatment Product Offerings
Table 44. Johnson & Johnson Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Merck & Co. Corporate Summary
Table 46. Merck & Co. Hematological Malignancy Treatment Product Offerings
Table 47. Merck & Co. Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 48. AstraZeneca Corporate Summary
Table 49. AstraZeneca Hematological Malignancy Treatment Product Offerings
Table 50. AstraZeneca Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Pfizer Corporate Summary
Table 52. Pfizer Hematological Malignancy Treatment Product Offerings
Table 53. Pfizer Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Amgen Corporate Summary
Table 55. Amgen Hematological Malignancy Treatment Product Offerings
Table 56. Amgen Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Eli Lilly Corporate Summary
Table 58. Eli Lilly Hematological Malignancy Treatment Product Offerings
Table 59. Eli Lilly Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 60. AbbVie Corporate Summary
Table 61. AbbVie Hematological Malignancy Treatment Product Offerings
Table 62. AbbVie Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Takeda Corporate Summary
Table 64. Takeda Hematological Malignancy Treatment Product Offerings
Table 65. Takeda Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Sanofi Corporate Summary
Table 67. Sanofi Hematological Malignancy Treatment Product Offerings
Table 68. Sanofi Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 69. Bayer Corporate Summary
Table 70. Bayer Hematological Malignancy Treatment Product Offerings
Table 71. Bayer Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)
Table 72. Biogen Idec Corporate Summary
Table 73. Biogen Idec Hematological Malignancy Treatment Product Offerings
Table 74. Biogen Idec Hematological Malignancy Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Hematological Malignancy Treatment Segment by Type in 2021
Figure 2. Hematological Malignancy Treatment Segment by Indication in 2021
Figure 3. Global Hematological Malignancy Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hematological Malignancy Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hematological Malignancy Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hematological Malignancy Treatment Revenue in 2021
Figure 8. By Type - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028
Figure 9. By Indication - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hematological Malignancy Treatment Revenue Market Share, 2017-2028
Figure 12. US Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hematological Malignancy Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hematological Malignancy Treatment Revenue Market Share, 2017-2028
Figure 24. China Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hematological Malignancy Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hematological Malignancy Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hematological Malignancy Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Roche Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Celgene Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bristol-Myers Squibb Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Johnson & Johnson Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck & Co. Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AstraZeneca Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pfizer Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Amgen Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eli Lilly Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. AbbVie Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Takeda Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Sanofi Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Bayer Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Biogen Idec Hematological Malignancy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)